Boryung and Abbott has set co-marketing for the pancreatic enzyme preparations ‘Creon’
.jpg)
Boryung and Abbott Korea will advance on co-marketing for ‘Creon’, an alternative drug for pancreatic exocrine dysfunction.
Boryung (president Tae-hong Choi)and Abbott Korea (president Yu-suk Jung) announced on the 1st that they made a contract for co-marketing of ‘Creon’, which is aneffective p...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
